Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.44 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 14/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097448 | 0.98 | STK17B (0.47) | STK17BSTK17ABRD4TDP1POLB | |
| SCHEMBL5030437 | 0.94 | POLB (0.41) | STK17BSTK17ABRD4TDP1POLB | |
| SCHEMBL5334549 | 0.90 | POLB (0.39) | STK17BSTK17ABRD4TDP1POLB | |
| SCHEMBL6096515 | 0.86 | TDP1 (0.41) | STK17BSTK17ABRD4TDP1POLB | |
| SCHEMBL5027847 | 0.83 | LATS1 (0.37) | STK17BSTK17ABRD4POLB | |
| SCHEMBL8137366 | 0.81 | BCHE (0.47) | BRD4MEN1GAAKMT2A | |
| SCHEMBL6095408 | 0.81 | BRD4 (0.42) | STK17BSTK17ABRD4 | |
| SCHEMBL6095773 | 0.81 | BRD4 (0.39) | STK17BSTK17ABRD4TDP1MEN1 | |
| SCHEMBL4773797 | 0.81 | POLB (0.41) | TDP1POLBMEN1GAAKMT2A | |
| SCHEMBL6098426 | 0.80 | BRD4 (0.47) | STK17BSTK17ABRD4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598192-B2 | Hydroxylamine substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-12-03 | — | — | US | disclosed |
| US-7897767-B2 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1682544-A4 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20090105295-A1 | HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. | 2009-02-12 | — | — | US | disclosed |
| EP-1685129-A4 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7098221-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1685129-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1682544-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050282854-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-12-22 | — | — | US | disclosed |
| US-20030195209-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-16 | — | — | US | disclosed |
| US-20030186949-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-20030176458-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-18 | — | — | US | disclosed |
| US-20030162806-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-28 | — | — | US | disclosed |
| WO-2003050119-A2 | UREA SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050118-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050117-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6545016-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6545017-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6525064-B1 | Immune response modifiers; can induce the biosynthesis of various cytokines; | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176458-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | STK17B 3253/4885STK17A 3207/4885BRD4 463/4885 |
| US-20030195209-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | STK17B 3253/4885STK17A 3207/4885BRD4 463/4885 |
| US-20090105295-A1 | HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES | IL2, IL4, IFNG | STK17B 3025/4885STK17A 2425/4885BRD4 89/4885 |
| US-20050282854-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | STK17B 3251/4885STK17A 2848/4885BRD4 57/4885 |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IL2, IRF3 | STK17B 2402/4885STK17A 2090/4885BRD4 335/4885 |
| US-20030162806-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | STK17B 3251/4885STK17A 2848/4885BRD4 57/4885 |
| US-20030186949-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | STK17B 3251/4885STK17A 2848/4885BRD4 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.